Allogene Therapeutics Stock Forecast
NASDAQ: ALLOHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
After hours: 1.39 -0.71%
ALLO analyst consensus
Consensus (12 analysts)
none
Avg. price target
$9.00+542.86%
- Strong buy 3
- Buy 8
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 12 Wall Street analysts covering Allogene Therapeutics (2026-10-08), 11 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $9.00, with a high estimate of $14.00 and a low estimate of $4.00. The average target implies upside of 542.9% from the current price of $1.40.
The spread between the highest and lowest targets is 250.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for ALLO.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 3 | 25% |
| Buy | 8 | 67% |
| Hold | 1 | 8% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $4.00 | +185.71% |
| Average target | $9.00 | +542.86% |
| High target | $14.00 | +900.00% |